Filing Flows › Comparisons › LAB vs NAMS
Standard Biotools vs NewAmsterdam Pharma Co N.V.: LAB and NAMS compared
Standard Biotools is the larger company: $19.4M of revenue in its latest quarter (Q3 2026) against $19.2M for NewAmsterdam Pharma Co N.V. (Q3 2026). NewAmsterdam Pharma Co N.V. is growing faster (55× against -0.9% a year earlier). Standard Biotools is more profitable, with an operating margin of -102.0% against -230.6%.
Where the money goes: LAB and NAMS
Standard Biotools (LAB) · Q3 2026
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
NewAmsterdam Pharma Co N.V. (NAMS) · Q3 2026
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
| Standard Biotools (LAB) | NewAmsterdam Pharma Co N.V. (NAMS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $19.4M | $19.2M |
| Revenue growth, Y/Y | -0.9% | 55× |
| Operating margin | -102.0% | -230.6% |
| Net earnings | $13.5M | −$17.4M |
| Net margin | 69.6% | -90.7% |
| Operating cash flow | −$6.2M | −$39.8M |
Where the revenue comes from
Standard Biotools
- Product: $14.3M (74%)
- Services and Other Revenue: $5.1M (26%)
Questions
Which is bigger, Standard Biotools or NewAmsterdam Pharma Co N.V.?
Standard Biotools is the larger company: $19.4M of revenue in its latest quarter (Q3 2026) against $19.2M for NewAmsterdam Pharma Co N.V. (Q3 2026).
Is Standard Biotools or NewAmsterdam Pharma Co N.V. growing faster?
NewAmsterdam Pharma Co N.V. is growing faster (55× against -0.9% a year earlier).
Which is more profitable, Standard Biotools or NewAmsterdam Pharma Co N.V.?
Standard Biotools is more profitable, with an operating margin of -102.0% against -230.6%.
More: Standard Biotools earnings · how Standard Biotools makes money · NewAmsterdam Pharma Co N.V. earnings · how NewAmsterdam Pharma Co N.V. makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.